Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00729365 · ClinicalTrials.gov registry record · Phase 3

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

A Phase 3 study, sponsored by Northwestern University.

Terminated
Registry status
Phase 3
Development phase
65
Enrollment target

NCT00729365: Clinical Trial Phase 3 study, sponsored by Northwestern University.

NCT00729365 is a Phase 3 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 65 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00729365, a Phase 3 study, was terminated before completion, sponsored by Northwestern University.

TERMINATED
Registry status
Phase 3
Development phase
65 participants
Enrollment target

Study Summary

The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who have normal blood pressure and urine albumin levels.

Interventions

  • DRUG Placebo
  • DRUG Ramipril

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2008-07
Est. Completion 2010-06
Phase Phase 3
Northwestern University

1,209 total trials

Why NCT00729365 stopped before completion

NCT00729365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00729365 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00729365 about?

NCT00729365 is a clinical study titled "PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)". The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who have normal blood pressure and urine albumin levels.

What is the current status of trial NCT00729365?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2008-07. Estimated completion is 2010-06.

What interventions are being tested in trial NCT00729365?

The interventions under investigation include: Placebo (DRUG), Ramipril (DRUG).

Who is sponsoring clinical trial NCT00729365?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00729365's enrollment target sits among peer trials

65 1797th of 2000 higher than 202 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00729365, the US trial registry maintained by the National Library of Medicine. NCT00729365 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.